Cargando…

Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial

BACKGROUND: The 52-week monotherapy with the dipeptidyl peptidase-4 inhibitor sitagliptin and the sulphonylurea glimepiride on early-phase insulin secretion in Japanese patients with type 2 diabetes mellitus (T2DM) is not known. METHODS: A randomized, parallel-group, open-label trial was conducted a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kondo, Yaeko, Harada, Norio, Hamasaki, Akihiro, Kaneko, Shizuka, Yasuda, Koichiro, Ogawa, Eiichi, Harashima, Shin-ichi, Yoneda, Hiroko, Fujita, Yoshihito, Kitano, Norikazu, Nakamura, Yoshio, Matsuo, Fujio, Shinji, Megumi, Hinotsu, Shiro, Nakayama, Takeo, Inagaki, Nobuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769515/ https://www.ncbi.nlm.nih.gov/pubmed/26925169 http://dx.doi.org/10.1186/s13098-016-0131-y

Ejemplares similares

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
por: Shimoda, Seiya, et al.
Publicado: (2013)

Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks
por: Kadowaki, Takashi, et al.
Publicado: (2012)

Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study
por: Yoon, Kun Ho, et al.
Publicado: (2011)

Insulin Secretion and Risk for Future Diabetes in Subjects with a Nonpositive Insulinogenic Index
por: Aono, Daisuke, et al.
Publicado: (2018)

Regulation of Adropin by Sitagliptin monotherapy in participants with newly diagnosed type 2 Diabetes
por: Wang, Qiu, et al.
Publicado: (2022)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus
por: Cho, Eun-Hee, et al.
Publicado: (2020)

Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes
por: Tajima, Naoko, et al.
Publicado: (2013)

Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
por: Kubota, Akira, et al.
Publicado: (2012)

Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats
por: Zhang, Minchun, et al.
Publicado: (2019)

Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials
por: Zhu, Hongmei, et al.
Publicado: (2013)

Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial
por: Sidelmann Christensen, Alexander, et al.
Publicado: (2018)

Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy
por: Kaku, Kohei, et al.
Publicado: (2014)

The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy: A retrospective analysis
por: Pantalone, Kevin M., et al.
Publicado: (2010)

Long‐term safety and efficacy of a novel once‐weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52‐week open‐label, phase 3 study
por: Inagaki, Nobuya, et al.
Publicado: (2016)

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2018)

Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes
por: Gudipaty, Lalitha, et al.
Publicado: (2014)

Efficacy of Combination Therapy With Sitagliptin and Low-Dose Glimepiride in Japanese Patients With Type 2 Diabetes
por: Ishii, Hiroaki, et al.
Publicado: (2014)

Effect of sitagliptin and glimepiride on C-reactive protein (CRP) in overweight Type-2 diabetic patients
por: Hussain, Mazhar, et al.
Publicado: (2019)

Transitional Polytherapy: Tricks of the Trade for Monotherapy to Monotherapy AED Conversions
por: Garnett, William R, et al.
Publicado: (2009)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

Modulation of Adipocytokines Production and Serum NEFA Level by Metformin, Glimepiride, and Sitagliptin in HFD/STZ Diabetic Rats
por: Saad, Mohamed I., et al.
Publicado: (2015)

Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
por: Kim, Hyun Min, et al.
Publicado: (2015)

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Ahrén, Bo, et al.
Publicado: (2010)

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
por: Lavalle-González, F. J., et al.
Publicado: (2013)

Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost
por: Imasawa, Mitsuhiro, et al.
Publicado: (2016)

Evaluating the Short-Term Cost-Effectiveness of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Failing Metformin Monotherapy in the United States
por: Langer, Jakob, et al.
Publicado: (2013)

HGG-52. SUSTAINED RESPONSE TO CRIZOTINIB MONOTHERAPY IN AN INFANT WITH GOPC-ROS1 FUSED CONGENITAL HEMISPHERIC GLIOMA
por: Lulla, Rishi, et al.
Publicado: (2020)

Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post‐hoc analyses of a randomized, double‐blind, phase III study
por: Shi, Li Xin, et al.
Publicado: (2019)

Sitagliptin 100 mg vs glimepiride 1–3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM)
por: Kesavadev, Jothydev, et al.
Publicado: (2017)

Quetiapine monotherapy for bipolar depression
por: Thase, Michael E
Publicado: (2008)

Topiramate Monotherapy in Infantile Spasm
por: Kwon, Young-Se, et al.
Publicado: (2006)

Monotherapy with liraglutide – Points to be focussed
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2019)

Resistance to Antimalarial Monotherapy Is Cyclic
por: Weitzman, Rachel, et al.
Publicado: (2022)

Commentary: Ticagrelor monotherapy—Not for CABG?
por: Sandner, Sigrid, et al.
Publicado: (2022)

Lithium Monotherapy in Graves Thyrotoxicosis
por: Larkworthy, James, et al.
Publicado: (2023)

Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure
por: Fujita, Kohei, et al.
Publicado: (2021)

The insulinogenic effect of whey protein is partially mediated by a direct effect of amino acids and GIP on β-cells
por: Salehi, Albert, et al.
Publicado: (2012)

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes
por: Bode, B W, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_4qptsr9dg4t1i4p6nlijrocivu